Evidence from epidemiological studies indicate that overweight/insulin resistant women seem to benefit more from the use of metformin in terms of BC incidence as compared to other antidiabetic drugs; these results could be related to the indirect anti-cancer effect of metformin through the reduction of systemic insulin levels and hyperglycemia [49]. This evidence concerns the gene INS and cancer.